Shaily Engineering Plastics Q2 Revenue Rises 24% to ₹319.5 Crore
Key highlights
- Shaily reported record Q2 FY27 consolidated revenue of ₹319.53 crore, up 24% year-on-year.
- Q2 FY27 EBITDA rose 25% to ₹101.8 crore, with a 31.9% EBITDA margin.
- Healthcare contributed 55% of Q2 FY27 revenue and grew 78% year-on-year.
- H1 FY27 consolidated revenue reached ₹600.20 crore, while net profit attributable to shareholders rose 18% to ₹109.28 crore.
powered by IRIS

Shaily Engineering Plastics Limited reported record consolidated revenue of ₹319.5 crore in Q2 FY27, up 24% year-on-year, while EBITDA rose 25% to ₹101.8 crore and healthcare contributed 55% of quarterly sales. The September-quarter performance marked the company’s first quarterly EBITDA above ₹100 crore.
Know Shaily Engineering Plastics inside out
Results, valuation, peers and who's buying, in one view.
What did Shaily report for Q2 FY27?
Shaily reported consolidated revenue of ₹319.53 crore for Q2 FY27, compared with ₹256.65 crore in Q2 FY26. Revenue was also 14% higher sequentially, according to management’s earnings call for the quarter ended September 30, 2026. The company described this as its highest-ever quarterly revenue.
Quarterly EBITDA increased to ₹101.8 crore from about ₹82 crore a year earlier, representing 25% growth. EBITDA margin was 31.9%, compared with 31.8% in the corresponding quarter of the previous financial year. The company said the quarter was its first in which EBITDA crossed ₹100 crore.
Net profit attributable to shareholders rose 20% to ₹61.27 crore from ₹51.25 crore. Profit before tax increased 28% to ₹84.5 crore, while the profit-before-tax margin expanded by 90 basis points to 26.5%. However, PAT margin was 19.2%, compared with 20.0% in Q2 FY26.
Why did healthcare lead Shaily’s growth?
Healthcare was Shaily’s primary growth segment in Q2 FY27, contributing 55% of consolidated revenue and growing 78% year-on-year. Management identified the segment as the main engine of the business during the quarter, reflecting the company’s increased healthcare manufacturing contribution.
The company’s earnings materials linked its performance to healthcare demand, including GLP-1 pen injector demand. The call also referred to launches in India beginning in March, approval of a generic in Canada in April, and approval of Brazil’s first generic in August. The provided information does not quantify the financial contribution of individual launches or markets.
In contrast, the consumer business faced weaker home-furnishings demand. Shaily reported that consumer revenue declined during the quarter. This contrast is important because the stronger healthcare mix supported overall growth even as demand conditions remained uneven in parts of the consumer portfolio.
How did Shaily perform in the first half of FY27?
Shaily’s first-half consolidated revenue rose 19% year-on-year to ₹600.20 crore, while EBITDA increased 22% to ₹185.1 crore. Net profit attributable to shareholders for H1 FY27 was ₹109.28 crore, up 18% from the year-earlier period.
H1 EBITDA margin stood at 30.8%, and gross margin was 58.4%. The H1 gross margin was 310 basis points higher than the 55.3% reported in the prior-year period, indicating a meaningful improvement in the profitability of revenue before operating expenses.
Got a follow-up? Ask IRIS
What drove Shaily’s margins and costs in Q2 FY27?
Shaily’s Q2 gross margin recovered to 60.0%, around 70 basis points above the previous year, after cost pressures highlighted in the first quarter. The improvement in gross margin, along with the larger healthcare contribution, supported the increase in EBITDA despite continued pressure in the consumer business.
Raw-material costs were ₹127.7 crore in Q2 FY27. Employee expenses were ₹34.8 crore, while other expenses, including power and fuel, were ₹59.9 crore. Cash PAT, which includes depreciation, was ₹75.5 crore, up 19% year-on-year.
The financial data shows that revenue growth was accompanied by an improvement in operating profitability. Still, the slight year-on-year decline in PAT margin means that the rise in net profit did not fully match the expansion in EBITDA margin. The reported figures do not provide a detailed reconciliation for every item affecting the difference.
What does the quarter mean for Shaily investors and operations?
Shaily’s Q2 results show that healthcare has become the company’s largest reported revenue driver, with a 55% share of sales and 78% year-on-year growth. That shift helped the company deliver record revenue and cross the ₹100 crore quarterly EBITDA threshold despite a decline in consumer revenue.
For investors, the key operating indicators are the healthcare revenue mix, gross-margin recovery and the pace of EBITDA growth. Revenue increased 24%, EBITDA grew 25% and net profit rose 20%, showing broad earnings growth, although consumer demand conditions and the lower PAT margin remain relevant factors in assessing quarterly performance.
The company’s results were presented on October 30, 2026, for the quarter ended September 30, 2026. Management said the investor presentation and quarterly results had been filed with the stock exchanges, and the call recording was made available on the company’s website.
Conclusion
Shaily delivered a record Q2 FY27 with ₹319.53 crore in revenue, ₹101.8 crore in EBITDA and ₹61.27 crore in net profit attributable to shareholders. Healthcare drove the result, contributing more than half of quarterly revenue and growing faster than the company’s overall sales, while consumer revenue declined amid weak home-furnishings demand.
The next reported indicators to watch are healthcare’s revenue share, consumer-demand conditions, gross-margin performance and the company’s ability to sustain EBITDA above ₹100 crore in a quarter. Management also highlighted launches and regulatory approvals across India, Canada and Brazil, though the disclosed materials did not provide quantified future revenue targets for these developments.


